During the past decade, Farabi General Hospital conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Farabi General Hospital" are "Hepatitis B, Chronic" (2 trials), "Chronic Hepatitis B" (1 trials), "Hepatocellular Carcinoma" (1 trials), "Natural Blood and Blood Product Toxicity" (1 trials) and "Quality of Life" (1 trials). Many other conditions were trialed in "Farabi General Hospital" in a lesser frequency.

Most popular intervention types in "Farabi General Hospital" are "Drug" (4 trials), "Biological" (2 trials), "Dietary Supplement" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Oncoxin" (2 trials), "Erythropoietin alpha" (1 trials), "NASVAC" (1 trials), "Pegasys" (1 trials) and "Pegylated interferon alpha 2b" (1 trials). Other intervention names were less common.

The vast majority of trials in "Farabi General Hospital" are 5 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Farabi General Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Farabi General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Farabi General Hospital, 4 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".